A randomized comparison of antiretroviral therapy alone versus antiretroviral therapy with a 'kick-and-kill' approach, on measures of the HIV reservoir amongst participants with recent HIV infection: the RIVER trial
File(s)RIVER_MANUSCRIPT_CLEAN_ACCEPTED.docx (82.32 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Background: Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells. Approaches that force HIV transcription from these cells, making them susceptible to killing - termed ‘kick and kill’ - have been explored as a strategy towards an HIV cure. RIVER is the first randomized trial to determine the impact of ART alone versus ART plus ‘kick-and-kill’ on markers of the HIV reservoir.
Methods: RIVER (Trial registration: NCT02336074) was an open-label, multicenter, 1:1 randomized controlled trial of ART-only (control) versus ART plus the histone deacetylase inhibitor vorinostat (the ‘kick’) and replication-deficient viral vector vaccines encoding conserved HIV sequences ChAdV63.HIVconsv-prime, MVA.HIVconsv-boost T-cell vaccination (the ‘kill’) (ART+V+V; intervention) in HIV-positive adults treated in recent HIV-infection. The primary endpoint was total HIV DNA in peripheral blood CD4+ T-cells at weeks 16 and 18 post-randomization. Secondary endpoints included safety, alternative measures of the HIV reservoir including quantitative viral outgrowth, HIV-specific T-cell frequencies, and CD8+ T-cell mediated viral inhibition.
Findings: Between December 2015 and November 2017, 60 HIV-positive male participants were randomized (computer-based and stratified by time since diagnosis; 30 participants in each trial arm) and completed the study interventions, with no loss-to-follow-up. There were no intervention-related serious adverse events. Mean total HIV DNA at weeks 16 and 18 was 3.02 log10 copies HIV DNA/106 CD4+ T-cells in the control and 3.06 log10 copies HIV DNA/106 CD4+ T-cells in the intervention arm, with no statistically significant difference (mean difference of 0.04 (95%CI -0.03, 0.11) log10 total HIV DNA copies/106 CD4+ T-cells (p=0.26)).
Interpretation: This ‘kick-and-kill’ approach conferred no significant benefit compared to ART alone on measures of the HIV reservoir. Although this does not disprove the ‘kick and kill’ strategy, for future trials significant enhancement of both ‘kick’ and ‘kill’ agents will be required.
Methods: RIVER (Trial registration: NCT02336074) was an open-label, multicenter, 1:1 randomized controlled trial of ART-only (control) versus ART plus the histone deacetylase inhibitor vorinostat (the ‘kick’) and replication-deficient viral vector vaccines encoding conserved HIV sequences ChAdV63.HIVconsv-prime, MVA.HIVconsv-boost T-cell vaccination (the ‘kill’) (ART+V+V; intervention) in HIV-positive adults treated in recent HIV-infection. The primary endpoint was total HIV DNA in peripheral blood CD4+ T-cells at weeks 16 and 18 post-randomization. Secondary endpoints included safety, alternative measures of the HIV reservoir including quantitative viral outgrowth, HIV-specific T-cell frequencies, and CD8+ T-cell mediated viral inhibition.
Findings: Between December 2015 and November 2017, 60 HIV-positive male participants were randomized (computer-based and stratified by time since diagnosis; 30 participants in each trial arm) and completed the study interventions, with no loss-to-follow-up. There were no intervention-related serious adverse events. Mean total HIV DNA at weeks 16 and 18 was 3.02 log10 copies HIV DNA/106 CD4+ T-cells in the control and 3.06 log10 copies HIV DNA/106 CD4+ T-cells in the intervention arm, with no statistically significant difference (mean difference of 0.04 (95%CI -0.03, 0.11) log10 total HIV DNA copies/106 CD4+ T-cells (p=0.26)).
Interpretation: This ‘kick-and-kill’ approach conferred no significant benefit compared to ART alone on measures of the HIV reservoir. Although this does not disprove the ‘kick and kill’ strategy, for future trials significant enhancement of both ‘kick’ and ‘kill’ agents will be required.
Date Issued
2020-03-14
Date Acceptance
2019-11-15
Citation
The Lancet, 2020, 395 (10227), pp.888-898
ISSN
0140-6736
Publisher
Elsevier
Start Page
888
End Page
898
Journal / Book Title
The Lancet
Volume
395
Issue
10227
Copyright Statement
© 2020 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
Medical Research Council (MRC)
Medical Research Council (MRC)
Identifier
https://www.sciencedirect.com/science/article/pii/S0140673619329903?via%3Dihub
Grant Number
MR/L00528X/1
MR/N001265/1
Subjects
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
LATENCY-REVERSING AGENTS
VIRAL LOAD
DNA
REACTIVATION
INHIBITOR
CAPACITY
PREDICTS
SIZE
AIDS Vaccines
Adult
Anti-Retroviral Agents
DNA, Viral
Disease Reservoirs
HIV Infections
Histone Deacetylase Inhibitors
Humans
Male
Transcription, Genetic
Treatment Outcome
Vorinostat
RIVER trial study group
Humans
HIV Infections
DNA, Viral
AIDS Vaccines
Anti-Retroviral Agents
Treatment Outcome
Disease Reservoirs
Transcription, Genetic
Adult
Male
Histone Deacetylase Inhibitors
Vorinostat
General & Internal Medicine
11 Medical and Health Sciences
Publication Status
Published
Date Publish Online
2020-02-19